Project Grant R43CA306207
Award Date 9/24/25
Completion Date 8/31/26
Dollars Obligated $353K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- The National Cancer Institute awarded a $571,271 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Texas Health Science Center at Houston. The goal of this 5-year research project is to develop a targeted therapy for the treatment of metastatic castration-resistant prostate cancer, an aggressive form of the disease with limited treatment options. The project will explore using a small molecule drug conjugate that targets the prostate-specific membrane...
- This federal Project Grant award, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports the development of a novel, targeted small molecule inhibitor called TRE-515 by Trethera Corp, a clinical-stage biopharmaceutical company based in California. The $1,150,000 award will fund preclinical studies to evaluate TRE-515, which targets the deoxycytidine kinase (DCK) enzyme, as a potential combination therapy to prevent the DCK-mediated resistance mechanism in...
- This $1,022,522 Project Grant was awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research federal grant program (CFDA 93.395) to Isoprene Pharmaceuticals Inc. The project aims to develop VNPP433-3beta (3B) as a novel therapeutic for all stages of prostate cancer. The key products and services include: The 3B compound, along with backup compounds 3B.HCl (VNPP548) and 3B.2HCl (VNPP595), are being evaluated as molecular glue degraders that simultaneously target the...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $799,962 to Tripill Biotechnology, Corp. to develop radiolabeled PSMA agents with low salivary gland uptake for improved prostate cancer imaging and therapy. The key products and services to be delivered include: Constructing PSMA derivative compounds, such as NOTA-UNC-PSMA2, that can selectively reduce salivary gland uptake while maintaining high tumor uptake in prostate...
- This federal Project Grant award of $545,078, funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), is supporting research at The Johns Hopkins University to investigate the use of radiopharmaceutical therapy in combination with inhibition of glutamine metabolism as a novel therapeutic strategy for prostate cancer and renal cell carcinoma. The project aims to systematically evaluate the effect of prostate-specific membrane antigen (PSMA)-based radiopharmaceutical...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $404,972 to the University of California, Los Angeles (UCLA) to conduct research on overcoming radiopharmaceutical therapy resistance in prostate cancer. The key focus is to investigate how the enzyme ENPP1 impacts the effectiveness of PSMA-targeting radiopharmaceutical therapy (RPT) by regulating immune signaling pathways in the tumor microenvironment. The research aims to define...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $185,760 to The Regents of the University of California, San Francisco (UCSF) to develop a novel combination therapy for treating metastatic castration-resistant prostate cancer (mCRPC). The project aims to co-deliver an antibody-drug conjugate (MMAE) and an alpha particle radioactive isotope (Actinium-225) directly to cancer cells, creating a synergistic effect to combat...
- This federal Project Grant award of $192,564 from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) supports Yale University's research to develop an innovative dual-target protein degrader that simultaneously inhibits lineage plasticity and therapy resistance drivers in metastatic castration-resistant prostate cancer (mCRPC). The research aims to overcome mCRPC's remarkable adaptability and lineage switching, which enable evasion of targeted therapies....
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $435,773 to the University of Maryland, Baltimore to develop an engineered prodrug that selectively delivers a potent cytotoxin to tumor cells expressing hyperactive membrane-anchored serine proteases. The goal is to create an effective therapeutic strategy to target metastatic solid tumors, including ovarian, lung, and colon cancers, which often respond poorly to current...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The University of Texas Southwestern Medical Center provides $472,458 to conduct research aimed at overcoming mechanisms of PTPN1 driving therapy- and castration-resistant prostate cancer. The 5-year project, starting December 1, 2024, will investigate the regulation of the PTPN1 gene and its role in the transition of prostate cancer cells to a therapy-resistant neuroendocrine...